Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2776 to 2790 of 7688 results

  1. Our charter

    An outline of the roles and responsibilities of the National Institute for Health and Care Excellence

  2. Our principles

    An outline of the key principles that are universal to all of NICE's guidance and standards.

  3. Consultation on changes to technology appraisals and highly specialised technologies

    NICE and NHS England have launched a 12 week consultation on changes to the arrangements for evaluating and funding drugs and other health technologies appraised through NICE’s Technology Appraisal (TA) and Highly Specialised Technologies (HST) programmes.

  4. Technology appraisal data

    Explore data about our technology appraisal guidance

  5. Data collection agreement

    This agreement relates to treating cystic fibrosis patients with: Ivacaftor, tezacaftor and elexacaftor (Kaftrio®) in combination with ivacaftor for

  6. Technology appraisal methods and processes used before 2022

    We use 3 processes for assessing technologies: the single technology appraisal, the multiple technology appraisal and the fast track appraisal.

  7. MTA process timeline

    These are the main stages in the multiple technology appraisal process used before April 2018. It applies to evaluations that started before 1...

  8. STA process timeline, pre-April 2018

    These are the main stages in the single technology appraisal (STA) process used before April 2018.

  9. Chemotherapy dose standardisation: NICE position statement

    NICE has been collaborating with NHS England on the Chemotherapy Dose Standardisation initiative which has been developed by the Medicines...

  10. Types of technology appraisal recommendation

    The technology appraisal committee can make 5 types of recommendation: Recommended, Optimised, Recommended for use in the Cancer Drugs Fund, Only in research, and Not recommended.

  11. Position statement on use of the EQ-5D-5L value set for England (updated October 2019)

    Our position on use of the EQ-5D-5L valuation set for England

  12. Modular updates for our technology appraisal guidance

    On this page, you'll find all our modular updates relating to our technology appraisal guidance. October 2023 NICE response to consultation on the...

  13. Biosimilar technologies: NICE position statement

    There are 2 different points of the lifecycle of a NICE Technology Appraisal at which consideration of reference to or inclusion of a biosimilar is...

  14. Biosimilar technologies: NICE position statement - information for the public

    Biosimilar medicines – NICE's approach A biological medicine is any medicinal product made by or derived from a biological (natural) source, for...

  15. Participation in clinical trials and subsequent access to drugs appraised by NICE: a statement on the applicability of technology appraisal guidance

    Patients taking part in clinical trials may receive drugs which have been evaluated by NICE technology appraisal guidance. Queries have been raised...